Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Cancer / Tumors & CD134 / OX40 receptor

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

CD134 / OX40 receptor expression has been observed on tumor-infiltrating lymphocytes (TILs) in various cancer types, including head and neck, ovarian, gastric, breast, and colorectal cancers
Deng et al. 2019 Onco Targets Ther. 12: 7347-7353

This expression pattern makes CD134 / OX40 receptor an attractive target for [cancer immunotherapy](brain://1tU2RVzLJES1B4eoBqwBpQ/CancerImmunotherapyImmunoOncology…

References (Sources)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
Deng et al. 2019 Onco Targets Ther. 12: 7347-7353
Review
OX40 and OX40L Interaction in Cancer
Lu 2021 Curr Med Chem. 28(28): 5659-5673
Review
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard et al. 2014a Immunol Cell Biol. 92(6): 475-80
Ox40 is a potent immune-stimulating target in late-stage cancer patients
Curti et al. 2013 Cancer Res 73: 7189-98
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
Moran et al., 2013
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Cancer / Tumors & CD134 / OX40 receptor

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat